Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation (AHSCT) is an increasingly used curative treatment for some solid tumors in children. Instead of allogeneic transplantation, the risk of developing graft-versus-host disease (GvHD) is much lower after AHSCT. Although the clinical findings of auto-GV...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-06-01
|
| Series: | Journal of Pediatric Research |
| Subjects: | |
| Online Access: |
http://jpedres.org/archives/archive-detail/article-preview/successful-treatment-of-refractory-graft-versus-ho/52013
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308764261318656 |
|---|---|
| author | Nurşah Eker Burcu Tufan Taş Ömer Doğru Emel Şenay Ayşe Gülnur Tokuç Ahmet Koç |
| author_facet | Nurşah Eker Burcu Tufan Taş Ömer Doğru Emel Şenay Ayşe Gülnur Tokuç Ahmet Koç |
| author_sort | Nurşah Eker |
| collection | DOAJ |
| description | Autologous hematopoietic stem cell transplantation (AHSCT) is an increasingly used curative treatment for some solid tumors in children. Instead of allogeneic transplantation, the risk of developing graft-versus-host disease (GvHD) is much lower after AHSCT. Although the clinical findings of auto-GVHD are mild and self-limited in most cases, rare cases may be severe and need intensive immunosuppressive treatment. Here, we present a case who underwent autologous HSCT due to relapsed neuroblastoma, developed steroid-refractory GvHD after AHSCT, and achieved remission using ruxolitinib. A 12 years old female patient was diagnosed with relapsed neuroblastoma. After metaiodobenzylguanidine treatment, AHSCT was performed, and the status of the disease was a very good partial response at the time of transplantation. Our patient was diagnosed with severe and steroid-refractory GvHD with skin involvement after AHSCT. We used ruxolitinib with extracorporeal photopheresis because of the essential side effects of the other drugs and got a very good response. Over the following five months, there was no recurrence of GvHD. She was in complete remission of neuroblastoma after two years of AHSCT. It is crucial to keep in mind that GvHD may develop after AHSCT. Ruxolitinib is an effective treatment for GvHD also after AHSCT. Further studies and case reports are needed to understand the disease’s pathogenesis and regulate appropriate treatment. |
| format | Article |
| id | doaj-art-1aff4c70f81a463bb5ff333c6e6f1fad |
| institution | Kabale University |
| issn | 2147-9445 2587-2478 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Journal of Pediatric Research |
| spelling | doaj-art-1aff4c70f81a463bb5ff333c6e6f1fad2025-08-20T03:54:23ZengGalenos Publishing HouseJournal of Pediatric Research2147-94452587-24782022-06-019219720010.4274/jpr.galenos.2022.6933513049054Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell TransplantationNurşah Eker0Burcu Tufan Taş1Ömer Doğru2Emel Şenay3Ayşe Gülnur Tokuç4Ahmet Koç5 Marmara University Faculty of Medicine, Department of Pediatric Hematology Oncology, İstanbul, Turkey Marmara University, Pendik Training and Research Hospital, Clinic of Pediatric Hematology Oncology, İstanbul, Turkey Marmara University Faculty of Medicine, Department of Pediatric Hematology Oncology, İstanbul, Turkey Marmara University, Pendik Training and Research Hospital, Clinic of Pediatric Hematology Oncology, İstanbul, Turkey Marmara University Faculty of Medicine, Department of Pediatric Hematology Oncology, İstanbul, Turkey Marmara University Faculty of Medicine, Department of Pediatric Hematology Oncology, İstanbul, Turkey Autologous hematopoietic stem cell transplantation (AHSCT) is an increasingly used curative treatment for some solid tumors in children. Instead of allogeneic transplantation, the risk of developing graft-versus-host disease (GvHD) is much lower after AHSCT. Although the clinical findings of auto-GVHD are mild and self-limited in most cases, rare cases may be severe and need intensive immunosuppressive treatment. Here, we present a case who underwent autologous HSCT due to relapsed neuroblastoma, developed steroid-refractory GvHD after AHSCT, and achieved remission using ruxolitinib. A 12 years old female patient was diagnosed with relapsed neuroblastoma. After metaiodobenzylguanidine treatment, AHSCT was performed, and the status of the disease was a very good partial response at the time of transplantation. Our patient was diagnosed with severe and steroid-refractory GvHD with skin involvement after AHSCT. We used ruxolitinib with extracorporeal photopheresis because of the essential side effects of the other drugs and got a very good response. Over the following five months, there was no recurrence of GvHD. She was in complete remission of neuroblastoma after two years of AHSCT. It is crucial to keep in mind that GvHD may develop after AHSCT. Ruxolitinib is an effective treatment for GvHD also after AHSCT. Further studies and case reports are needed to understand the disease’s pathogenesis and regulate appropriate treatment. http://jpedres.org/archives/archive-detail/article-preview/successful-treatment-of-refractory-graft-versus-ho/52013 autologous stem cell transplantationchildrengraft versus host diseaseruxolitinibsteroid-resistant |
| spellingShingle | Nurşah Eker Burcu Tufan Taş Ömer Doğru Emel Şenay Ayşe Gülnur Tokuç Ahmet Koç Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation Journal of Pediatric Research autologous stem cell transplantation children graft versus host disease ruxolitinib steroid-resistant |
| title | Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation |
| title_full | Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation |
| title_fullStr | Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation |
| title_full_unstemmed | Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation |
| title_short | Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation |
| title_sort | successful treatment of refractory graft versus host disease with ruxolitinib in a child after autologous stem cell transplantation |
| topic | autologous stem cell transplantation children graft versus host disease ruxolitinib steroid-resistant |
| url |
http://jpedres.org/archives/archive-detail/article-preview/successful-treatment-of-refractory-graft-versus-ho/52013
|
| work_keys_str_mv | AT nursaheker successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation AT burcutufantas successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation AT omerdogru successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation AT emelsenay successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation AT aysegulnurtokuc successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation AT ahmetkoc successfultreatmentofrefractorygraftversushostdiseasewithruxolitinibinachildafterautologousstemcelltransplantation |